metaEvidence - overview


			deaths (OS)
Extensive stage SCLC (Es-SCLC) - maintenance (M) Extensive stage SCLC (Es-SCLC) Extensive stage SCLC (Es-SCLC) - maintenance (M)
versus placebo
	nivolumab alone vs. placebo	1	0.84 [0.69; 1.02], 1 RCT, I2=0% inconclusive result
	nivolumab plus ipilimumab vs. placebo	1	0.92 [0.75; 1.12], 1 RCT, I2=0% inconclusive result
Extensive stage SCLC (Es-SCLC) - 1st Line (L1) Extensive stage SCLC (Es-SCLC) Extensive stage SCLC (Es-SCLC) - 1st Line (L1)
versus etoposide plus platin
	durvalumab plus etoposide and platin vs. etoposide plus platin	1	0.73 [0.59; 0.91], 1 RCT, I2=0% conclusive unassessable degree of certainty
	durvalumab plus tremelimumab plus SoC vs. etoposide plus platin	1	0.82 [0.68; 0.99], 1 RCT, I2=0% unassessable degree of certainty
versus placebo plus SoC
	atezolizumab plus SoC vs. placebo plus SoC	1	0.70 [0.54; 0.91], 1 RCT, I2=0% conclusive unassessable degree of certainty
	ipilimumab plus SoC vs. placebo plus SoC	1	0.94 [0.81; 1.09], 1 RCT, I2=0% inconclusive result
	pembrolizumab plus SoC vs. placebo plus SoC	1	0.80 [0.65; 0.99], 1 RCT, I2=0% unassessable degree of certainty